Literature DB >> 12904483

KCNQ/M currents in sensory neurons: significance for pain therapy.

Gayle M Passmore1, Alexander A Selyanko, Mohini Mistry, Mona Al-Qatari, Stephen J Marsh, Elizabeth A Matthews, Anthony H Dickenson, Terry A Brown, Stephen A Burbidge, Martin Main, David A Brown.   

Abstract

Neuronal hyperexcitability is a feature of epilepsy and both inflammatory and neuropathic pain. M currents [IK(M)] play a key role in regulating neuronal excitability, and mutations in neuronal KCNQ2/3 subunits, the molecular correlates of IK(M), have previously been linked to benign familial neonatal epilepsy. Here, we demonstrate that KCNQ/M channels are also present in nociceptive sensory systems. IK(M) was identified, on the basis of biophysical and pharmacological properties, in cultured neurons isolated from dorsal root ganglia (DRGs) from 17-d-old rats. Currents were inhibited by the M-channel blockers linopirdine (IC50, 2.1 microm) and XE991 (IC50, 0.26 microm) and enhanced by retigabine (10 microm). The expression of neuronal KCNQ subunits in DRG neurons was confirmed using reverse transcription-PCR and single-cell PCR analysis and by immunofluorescence. Retigabine, applied to the dorsal spinal cord, inhibited C and Adelta fiber-mediated responses of dorsal horn neurons evoked by natural or electrical afferent stimulation and the progressive "windup" discharge with repetitive stimulation in normal rats and in rats subjected to spinal nerve ligation. Retigabine also inhibited responses to intrapaw application of carrageenan in a rat model of chronic pain; this was reversed by XE991. It is suggested that IK(M) plays a key role in controlling the excitability of nociceptors and may represent a novel analgesic target.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12904483      PMCID: PMC6740665     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  131 in total

Review 1.  New and emerging pharmacological targets for neuropathic pain.

Authors:  Donald C Manning
Journal:  Curr Pain Headache Rep       Date:  2004-06

2.  Tune in to KCNQ.

Authors:  Clare H Munns; Michael J Caterina
Journal:  Nat Neurosci       Date:  2011-12-23       Impact factor: 24.884

3.  Some new insights into the molecular mechanisms of pain perception.

Authors:  David A Brown; Gayle M Passmore
Journal:  J Clin Invest       Date:  2010-04-26       Impact factor: 14.808

Review 4.  KCNQ potassium channels in sensory system and neural circuits.

Authors:  Jing-jing Wang; Yang Li
Journal:  Acta Pharmacol Sin       Date:  2015-12-21       Impact factor: 6.150

5.  Kv7.2 regulates the function of peripheral sensory neurons.

Authors:  Chih H King; Eric Lancaster; Daniela Salomon; Elior Peles; Steven S Scherer
Journal:  J Comp Neurol       Date:  2014-04-12       Impact factor: 3.215

6.  EAG channels expressed in microvillar photoreceptors are unsuited to diurnal vision.

Authors:  Esa-Ville Immonen; Andrew S French; Päivi H Torkkeli; Hongxia Liu; Mikko Vähäsöyrinki; Roman V Frolov
Journal:  J Physiol       Date:  2017-02-22       Impact factor: 5.182

7.  Cutaneous Aβ-Non-nociceptive, but Not C-Nociceptive, Dorsal Root Ganglion Neurons Exhibit Spontaneous Activity in the Streptozotocin Rat Model of Painful Diabetic Neuropathy in vivo.

Authors:  Laiche Djouhri; Asad Zeidan; Seham A Abd El-Aleem; Trevor Smith
Journal:  Front Neurosci       Date:  2020-05-25       Impact factor: 4.677

Review 8.  Flupirtine, a re-discovered drug, revisited.

Authors:  Istvan Szelenyi
Journal:  Inflamm Res       Date:  2013-01-16       Impact factor: 4.575

9.  Vasopressin stimulates action potential firing by protein kinase C-dependent inhibition of KCNQ5 in A7r5 rat aortic smooth muscle cells.

Authors:  Lioubov I Brueggemann; Christopher J Moran; John A Barakat; Jay Z Yeh; Leanne L Cribbs; Kenneth L Byron
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-10-27       Impact factor: 4.733

Review 10.  Neural KCNQ (Kv7) channels.

Authors:  David A Brown; Gayle M Passmore
Journal:  Br J Pharmacol       Date:  2009-03-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.